Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease:a multicentre,randomised,double-blind,parallel-group,phase 3b trial  

作　　者：Bruce E Sands 

机构地区：[1]不详

出　　处：《四川生理科学杂志》2022年第5期940-940,共1页Sichuan Journal of Physiological Sciences

摘　　要：Background:Active-comparator trials are important to inform patient and physician choice.We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients with moderately to severely active Crohn's disease.

关 键 词：PATIENTS centre moderately 

分 类 号：R57[医药卫生—消化系统]